Literature DB >> 24102017

Lung cancer surgery: an up to date.

Nikolaos Baltayiannis1, Michail Chandrinos, Dimitrios Anagnostopoulos, Paul Zarogoulidis, Kosmas Tsakiridis, Andreas Mpakas, Nikolaos Machairiotis, Nikolaos Katsikogiannis, Ioanna Kougioumtzi, Nikolaos Courcoutsakis, Konstantinos Zarogoulidis.   

Abstract

According to the International Agency for Research on Cancer (IARC) GLOBOCAN World Cancer Report, lung cancer affects more than 1 million people a year worldwide. In Greece according to the 2008 GLOBOCAN report, there were 6,667 cases recorded, 18% of the total incidence of all cancers in the population. Furthermore, there were 6,402 deaths due to lung cancer, 23.5% of all deaths due to cancer. Therefore, in our country, lung cancer is the most common and deadly form of cancer for the male population. The most important prognostic indicator in lung cancer is the extent of disease. The Union Internationale Contre le Cancer (UICC) and the American Joint Committee for Cancer Staging (AJCC) developed the tumour, node, and metastases (TNM) staging system which attempts to define those patients who might be suitable for radical surgery or radical radiotherapy, from the majority, who will only be suitable for palliative measures. Surgery has an important part for the therapy of patients with lung cancer. "Lobectomy is the gold standard treatment". This statement may be challenged in cases of stage Ia cancer or in patients with limited pulmonary function. In these cases an anatomical segmentectomy with lymph node dissection is an acceptable alternative. Chest wall invasion is not a contraindication to resection. En-bloc rib resection and reconstruction is the treatment of choice. N2 disease represents both a spectrum of disease and the interface between surgical and non-surgical treatment of lung cancer Evidence from trials suggests that multizone or unresectable N2 disease should be treated primarily by chemoradiotherapy. There may be a role for surgery if N2 is downstaged to N0 and lobectomy is possible, but pneumonectomy is avoidable. Small cell lung cancer (SCLC) is considered a systemic disease at diagnosis, because the potential for hematogenous and lymphogenic metastases is very high. The efficacy of surgical intervention for SCLC is not clear. Lung cancer resection can be performed using several surgical techniques. Video-assisted thoracoscopic surgery (VATS) lobectomy is a safe, efficient, well accepted and widespread technique among thoracic surgeons. The 5-year survival rate following complete resection of lung cancer is stage dependent. Incomplete resection rarely is useful and cures the patient.

Entities:  

Keywords:  Lung cancer; lobectomy; non-small cell lung cancer (NSCLC); small cell lung cancer (SCLC); staging; surgery; video-assisted thoracoscopic surgery (VATS)

Year:  2013        PMID: 24102017      PMCID: PMC3791495          DOI: 10.3978/j.issn.2072-1439.2013.09.17

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  106 in total

Review 1.  A rare case of primary intercostal leiomyoma: complete resection followed by reconstruction using a Gore-Tex(®) dual mesh.

Authors:  Takeo Nakada; Tadashi Akiba; Takuya Inagaki; Toshiaki Morikawa; Takao Ohki
Journal:  Ann Thorac Cardiovasc Surg       Date:  2013-08-30       Impact factor: 1.520

2.  Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database.

Authors:  Subroto Paul; Nasser K Altorki; Shubin Sheng; Paul C Lee; David H Harpole; Mark W Onaitis; Brendon M Stiles; Jeffrey L Port; Thomas A D'Amico
Journal:  J Thorac Cardiovasc Surg       Date:  2010-02       Impact factor: 5.209

3.  Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies.

Authors:  Christophe Doddoli; Benoit D'Journo; Françoise Le Pimpec-Barthes; Antoine Dujon; Christophe Foucault; Pascal Thomas; Marc Riquet
Journal:  Ann Thorac Surg       Date:  2005-12       Impact factor: 4.330

4.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

5.  The influence of hospital volume on survival after resection for lung cancer.

Authors:  P B Bach; L D Cramer; D Schrag; R J Downey; S E Gelfand; C B Begg
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

6.  Thoracoscopic lobectomy.

Authors:  T J Kirby; T W Rice
Journal:  Ann Thorac Surg       Date:  1993-09       Impact factor: 4.330

7.  Results of surgical treatment of lung cancer involving the diaphragm.

Authors:  K Yokoi; R Tsuchiya; T Mori; K Nagai; T Furukawa; S Fujimura; K Nakagawa; Y Ichinose
Journal:  J Thorac Cardiovasc Surg       Date:  2000-10       Impact factor: 5.209

Review 8.  Chest wall resection for lung cancer: indications and techniques.

Authors:  Erich Stoelben; Corinna Ludwig
Journal:  Eur J Cardiothorac Surg       Date:  2009-02-01       Impact factor: 4.191

9.  Lymph node evaluation achieved by open lobectomy compared with thoracoscopic lobectomy for N0 lung cancer.

Authors:  Robert E Merritt; Chuong D Hoang; Joseph B Shrager
Journal:  Ann Thorac Surg       Date:  2013-07-31       Impact factor: 4.330

10.  Video-assisted radiofrequency ablation for pleural disseminated non-small cell lung cancer.

Authors:  Yaxing Shen; Ming Zhong; Wei Jiang; Hong Fan; Hao Wang; Qun Wang
Journal:  BMC Surg       Date:  2013-06-13       Impact factor: 2.102

View more
  25 in total

1.  The status of WIF1 methylation in cell-free DNA is associated with the insusceptibility for gefitinib in the treatment of lung cancer.

Authors:  Zhijun Shen; Chen Chen; Jianhai Sun; Jingsong Huang; Shiguo Liu
Journal:  J Cancer Res Clin Oncol       Date:  2021-05-26       Impact factor: 4.553

2.  Clinicopathological and prognostic significance of Oct-4 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Shuang-Jiang Li; Jian Huang; Xu-Dong Zhou; Wen-Biao Zhang; Yu-Tian Lai; Guo-Wei Che
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

Review 3.  The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.

Authors:  Jon Zugazagoitia; Ana Belen Enguita; Juan Antonio Nuñez; Lara Iglesias; Santiago Ponce
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

4.  Shikonin enhances Adriamycin antitumor effects by inhibiting efflux pumps in A549 cells.

Authors:  Xuchun Liu; Gengyun Sun
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

5.  Discrimination of Malignant versus Benign Mediastinal Lymph Nodes Using Diffusion MRI with an IVIM Model.

Authors:  Li-Ping Qi; Wan-Pu Yan; Ke-Neng Chen; Zheng Zhong; Xiao-Ting Li; Kejia Cai; Ying-Shi Sun; Xiaohong Joe Zhou
Journal:  Eur Radiol       Date:  2017-09-19       Impact factor: 5.315

6.  A Prediction Model for Postoperative Pulmonary Complication in Pulmonary Function-Impaired Patients Following Lung Resection.

Authors:  Xiaowei Mao; Wei Zhang; Yi-Qian Ni; Yanjie Niu; Li-Yan Jiang
Journal:  J Multidiscip Healthc       Date:  2021-11-15

7.  Hypoxia and hypoxia-inducible factor 1 repress SEMA4B expression to promote non-small cell lung cancer invasion.

Authors:  Hong Jian; Bin Liu; Jie Zhang
Journal:  Tumour Biol       Date:  2014-01-29

8.  Log odds of positive lymph nodes are superior to other measures for evaluating the prognosis of non-small cell lung cancer.

Authors:  Peng Lv; Gang Chen; Peng Zhang
Journal:  Thorac Cancer       Date:  2014-10-23       Impact factor: 3.500

9.  Surgical Treatment in Small-Cell Lung Cancer: Single-Center Experience and Survival.

Authors:  Ahmet Ulusan; İbrahim Emre Tunca; Maruf Şanlı; Ahmet Feridun Işık
Journal:  Turk Thorac J       Date:  2021-05

10.  Shikonin Induces Apoptosis, Necrosis, and Premature Senescence of Human A549 Lung Cancer Cells through Upregulation of p53 Expression.

Authors:  Yueh-Chiao Yeh; Tsun-Jui Liu; Hui-Chin Lai
Journal:  Evid Based Complement Alternat Med       Date:  2015-02-09       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.